Toward neuroprotective treatments of Parkinson's disease.
作者信息
Kim Kwang-Soo
机构信息
Molecular Neurobiology Laboratory, Program in Neuroscience, Harvard Medical School, Boston, MA 02115;
Department of Psychiatry, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478.
出版信息
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3795-3797. doi: 10.1073/pnas.1703362114. Epub 2017 Mar 30.
Abstract
摘要
相似文献
1
Toward neuroprotective treatments of Parkinson's disease.帕金森病的神经保护治疗
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3795-3797. doi: 10.1073/pnas.1703362114. Epub 2017 Mar 30.
2
Neuroprotection in Parkinson's disease: an elusive goal.帕金森病中的神经保护：一个难以实现的目标。
Semin Neurol. 2007 Apr;27(2):106-12. doi: 10.1055/s-2007-971168.
3
Designing neuroprotection trials in Parkinson's disease.帕金森病神经保护试验的设计
Ann Neurol. 2003;53 Suppl 3:S100-7; discussion S107-9. doi: 10.1002/ana.10484.
4
Practical importance of neuroprotection in Parkinson's disease.神经保护在帕金森病中的实际重要性。
J Neurol. 2002 Oct;249 Suppl 3:III/53-6. doi: 10.1007/s00415-002-1311-2.
5
New preclinical model are required to discover neuroprotective compound in Parkinson's disease.需要新的临床前模型来发现治疗帕金森病的神经保护化合物。
Pharmacol Res. 2017 May;119:490. doi: 10.1016/j.phrs.2016.11.034. Epub 2016 Nov 25.
6
Trial designs used to study neuroprotective therapy in Parkinson's disease.用于研究帕金森病神经保护疗法的试验设计。
Mov Disord. 2013 Jan;28(1):86-95. doi: 10.1002/mds.24997. Epub 2012 Aug 23.
7
Neuroprotective therapy for Parkinson's disease.帕金森病的神经保护疗法
Exp Neurol. 1997 Mar;144(1):24-8. doi: 10.1006/exnr.1996.6383.
8
Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.神经保护和神经修复作为帕金森病的实验性治疗方法。
Exp Neurol. 2017 Dec;298(Pt B):137-147. doi: 10.1016/j.expneurol.2017.10.001. Epub 2017 Oct 5.
9
Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease.对胡安·塞古拉 - 阿吉拉尔评论的回应：需要新的临床前模型来发现帕金森病中的神经保护化合物。
Pharmacol Res. 2017 May;119:491-492. doi: 10.1016/j.phrs.2016.11.026. Epub 2016 Nov 24.
10
A responsive outcome for Parkinson's disease neuroprotection futility studies.帕金森病神经保护无效性研究的一个反应性结果。
Ann Neurol. 2005 Feb;57(2):197-203. doi: 10.1002/ana.20361.
引用本文的文献
1
Isolation and Characterization of Earthworm Peptides with Neuroprotective Effects in Parkinson's Disease Models.帕金森病模型中具有神经保护作用的蚯蚓肽的分离与鉴定
Molecules. 2025 Apr 28;30(9):1952. doi: 10.3390/molecules30091952.
2
Isolation of Lessertiosides A and B and Other Metabolites from and Their Neuroprotection Activity.从……中分离出莱瑟蒂oside A和B及其他代谢产物及其神经保护活性。 （原文中“from”后缺少具体来源信息）
Plants (Basel). 2024 Nov 1;13(21):3076. doi: 10.3390/plants13213076.
3
Quinones as Neuroprotective Agents.醌类作为神经保护剂。
Antioxidants (Basel). 2023 Jul 20;12(7):1464. doi: 10.3390/antiox12071464.
4
Closing the loop for patients with Parkinson disease: where are we?为帕金森病患者闭环：我们在哪里？
Nat Rev Neurol. 2022 Aug;18(8):497-507. doi: 10.1038/s41582-022-00674-1. Epub 2022 Jun 9.
5
Potent synthetic and endogenous ligands for the adopted orphan nuclear receptor Nurr1.经人为改造的孤儿核受体 Nurr1 的有效合成配体和内源性配体。
Exp Mol Med. 2021 Jan;53(1):19-29. doi: 10.1038/s12276-021-00555-5. Epub 2021 Jan 21.
6
Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT.年龄和性别校正对多巴胺转运体单光子发射计算机断层扫描诊断性能的影响。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1445-1459. doi: 10.1007/s00259-020-05085-2. Epub 2020 Oct 31.
7
The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis.Nurr1作为阿尔茨海默病相关发病机制的介导因子和治疗靶点的关键作用。
Aging Dis. 2020 May 9;11(3):705-724. doi: 10.14336/AD.2019.0718. eCollection 2020 May.
8
PGE1 and PGA1 bind to Nurr1 and activate its transcriptional function.PGE1 和 PGA1 与 Nurr1 结合并激活其转录功能。
Nat Chem Biol. 2020 Aug;16(8):876-886. doi: 10.1038/s41589-020-0553-6. Epub 2020 May 25.
9
Postural Instability in Parkinson's Disease: A Review.帕金森病中的姿势不稳：综述
Brain Sci. 2019 Sep 18;9(9):239. doi: 10.3390/brainsci9090239.
10
Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.美国新发帕金森病患者的治疗模式。
J Parkinsons Dis. 2019;9(4):749-759. doi: 10.3233/JPD-191636.
本文引用的文献
1
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.Nurr1:RXRα 异二聚体激活作为帕金森病的单一疗法。
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3999-4004. doi: 10.1073/pnas.1616874114. Epub 2017 Mar 27.
2
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.帕金森病的神经保护与治疗策略：最新观点
Int J Mol Sci. 2016 Jun 8;17(6):904. doi: 10.3390/ijms17060904.
3
Nurr1-Based Therapies for Parkinson's Disease.基于Nurr1的帕金森病治疗方法。
CNS Neurosci Ther. 2016 May;22(5):351-9. doi: 10.1111/cns.12536. Epub 2016 Mar 25.
4
4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery.用于治疗帕金森病的4-氨基-7-氯喹啉衍生物：对药物发现的启示
Expert Opin Drug Discov. 2016;11(4):337-41. doi: 10.1517/17460441.2016.1154529. Epub 2016 Mar 7.
5
Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.Nurr1和视黄酸X受体配体刺激多巴胺能神经元中的Ret信号传导，并可减轻α-突触核蛋白破坏的基因表达。
J Neurosci. 2015 Oct 21;35(42):14370-85. doi: 10.1523/JNEUROSCI.1155-15.2015.
6
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.核受体Nurr1激动剂增强其双重功能并改善帕金森病动物模型中的行为缺陷。
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8756-61. doi: 10.1073/pnas.1509742112. Epub 2015 Jun 29.
7
How to make a midbrain dopaminergic neuron.如何制造中脑多巴胺能神经元。
Development. 2015 Jun 1;142(11):1918-36. doi: 10.1242/dev.097394.
8
NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.NURR1 在帕金森病中的作用——从发病机制到治疗潜力。
Nat Rev Neurol. 2013 Nov;9(11):629-36. doi: 10.1038/nrneurol.2013.209. Epub 2013 Oct 15.
9
Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.低剂量贝沙罗汀治疗可挽救帕金森病模型中的多巴胺神经元并恢复其行为功能。
ACS Chem Neurosci. 2013 Nov 20;4(11):1430-8. doi: 10.1021/cn400100f. Epub 2013 Oct 11.
10
Deep-brain stimulation for Parkinson's disease.用于帕金森病的深部脑刺激
N Engl J Med. 2012 Oct 18;367(16):1529-38. doi: 10.1056/NEJMct1208070.
Zotero 插件